Xceleron Makes Key Appointments

Dr. David Roblin has been appointed to Xceleron’s board of directors in a non-executive capacity and Dr. Stuart Best has been named senior director of operations. Dr. Roblin joins the company from Pfizer Global R&D, where he most recently served as senior vice president R&D, research head and site director. His experience includes therapeutic areas within the spectrum of small and large molecule R&D.

Dr. Best joins the company from Merck, Scotland where he was head of Bioanalysis. Dr. Best has a distinguished career through leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry.

Xceleron chief executive officer Michael Butler said, “David Roblin is a hugely valuable addition to our board, and he understands the nature of the challenge that large pharma companies face and will help us to continue to meet that need. Stuart Best is a seasoned pharma manager with a deep understanding of pharmaceutical clients’ operational needs and recognized expertise in the application of novel analytical technologies in drug regulatory development.”